Analytical Data
-
基因名
CGRP
- Application
-
别名
CGRP；CALC1;Calcitonin gene-related peptide 1
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P06881
-
表达区间
83-119aa
-
氨基酸序列
ACDTATCVTHRLAGLLSRSGGVVKNNFVPTNVGSKAF
-
分子量
35.3 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CGRP (Calcitonin Gene-Related Peptide) is a neuropeptide that plays a significant role in the regulation of vascular tone and nociception. It is primarily produced in the trigeminal ganglia and is involved in migraine pathophysiology, where it contributes to the dilation of blood vessels and the transmission of pain signals. The overexpression of CGRP during migraine attacks has prompted extensive research into its potential as a therapeutic target. The development of recombinant CGRP proteins serves as an essential tool for understanding its biological functions and interactions. These recombinant proteins enable researchers to investigate CGRP's role in both healthy and pathological conditions, elucidating the mechanisms underlying migraine and other disorders mediated by CGRP. Additionally, the creation of CGRP receptor antagonists and monoclonal antibodies targeting CGRP has emerged as a promising therapeutic strategy, leading to the introduction of innovative migraine treatments. The ongoing research around CGRP and its recombinant forms continues to unveil new insights, aiming to improve the efficacy of migraine prophylaxis and enhance the overall management of related pain disorders.
